Characterization of novel, colitis associated pathobionts to identify therapeutic targets in the host immune response

表征新型结肠炎相关病原体，以确定宿主免疫反应中的治疗靶点

• 批准号: nhmrc : GNT1141564
• 负责人: Dr Samuel Forster
• 金额: $ 68.46万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/characterization-novel-colitis-immune-response/1348388
• 关键词: Characterization; novel; colitis; associated; pathobionts

Applying cutting edge methods to grow bacteria from the human gut, we have identified three species, two previously unknown, that are found in many inflammatory diseases including Inflammatory bowel disease, colorectal cancer and in cancer immunotherapy patients who experience colitis. By characterizing these bacteria and the immune response in human cells we are seeking to discover novel targetted methods to prevent colitis and gastrointestinal inflammation.

应用最先进的方法从人类肠道中培养细菌，我们已经确定了三个物种，其中两个是以前未知的，它们存在于许多炎症性疾病中，包括炎症性肠病，结直肠癌和经历结肠炎的癌症免疫治疗患者。通过表征这些细菌和人体细胞中的免疫反应，我们正在寻求发现新的靶向方法来预防结肠炎和胃肠道炎症。